Results 31 to 40 of about 62,619,193 (270)

Real-World Dose Adjustment and Switching of Interleukin-17/23 Inhibitors for Thai Psoriasis

Dermatology Research and Practice
Interleukin (IL)-17 and IL-23 inhibitors have transformed psoriasis care, delivering high clearance rates and quality-of-life gains. Nevertheless, inadequate response or adverse events can lead to treatment discontinuation or biologic switching.
Chayada Chaiyabutr, Teerapat Paringkarn, Thanakorn Woramongkol, Thrit Hutachoke, Narumol Silpa-Archa, Leena Chularojanamontri, Chanisada Wongpraparut   +6 more
doaj   +2 more sources

TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: therapeutic utility in the era of IL-17 and IL-23 inhibitors. [PDF]

J Psoriasis Psoriatic Arthritis, 2022
Psoriasis is a chronic inflammatory condition for which eleven FDA-approved biologic therapies are approved. Over the past decade, studies have documented the higher efficacy of IL-17 and IL-23 inhibitors for the treatment of psoriasis compared to the ...
Hong JJ, Hadeler EK, Mosca ML, Brownstone ND, Bhutani T, Liao WJ.   +5 more
europepmc   +2 more sources

The Use of IL-17 and IL-23 Inhibitors in Swedish Clinical Practice: A Register-Based Analysis.

Dermatology, 2023
BACKGROUND: Interleukin (IL) inhibitors have made completely cleared skin achievable for many patients with moderate to severe psoriasis in clinical trial settings. Few observational studies assess treatment response in accordance with treatment goals in
Norlin JM, Löfvendahl S, Schmitt-Egenolf M.   +2 more
europepmc   +2 more sources

Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis). [PDF]

Front Immunol, 2023
Introduction: The development of several effective biological drugs for moderate-to-severe plaque psoriasis has dramatically changed the lives of patients.
Gargiulo L, Ibba L, Malagoli P, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Megna M, Mercuri SR, Travaglini M, Costanzo A, Narcisi A.   +20 more
europepmc   +4 more sources

Living with Psoriasis Vulgaris and Multi-Treatment Failure: A Patient and Dermatologist Perspective

Dermatology and Therapy, 2023
Psoriasis vulgaris is a systemic, chronic inflammatory disease affecting 2–3% of the population. Recent advances in the understanding of the pathophysiology of psoriatic disease have facilitated the development of novel therapeutic options with improved ...
Riley K. Spencer, Kareem G. Elhage, Joy Q. Jin, Mitchell S. Davis, Marwa Hakimi, Tina Bhutani, Howard Chang, Wilson Liao   +7 more
doaj   +1 more source

IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors. [PDF]

Ann Rheum Dis, 2021
To determine the relationship between synovial versus skin transcriptional/histological profiles in patients with active psoriatic arthritis (PsA) and explore mechanistic links between diseased tissue pathology and clinical outcomes.Twenty-seven active PsA patients were enrolled in an observational/open-label study and underwent biopsies of synovium ...
Nerviani A, Boutet MA, Tan WSG, Goldmann K, Purkayastha N, Lajtos TA, Hands R, Lewis M, Kelly S, Pitzalis C.   +9 more
europepmc   +5 more sources

Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study. [PDF]

Am J Clin Dermatol
Background: Tuberculosis has a major global impact. Immunocompetent hosts usually control this disease, resulting in an asymptomatic latent tuberculosis infection (LTBI).
Torres T, Chiricozzi A, Puig L, Lé AM, Marzano AV, Dapavo P, Dauden E, Carrascosa JM, Lazaridou E, Duarte G, Carvalho AVE, Romiti R, Rompoti N, Teixeira L, Abreu M, Ippoliti E, Maronese CA, Llamas-Velasco M, Vilarrasa E, Del Alcázar E, Daponte AI, Papoutsaki M, Carugno A, Bellinato F, Gisondi P.   +24 more
europepmc   +4 more sources

Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources

The Lancet Regional Health. Europe, 2022
Summary: Background: Biologics directed against the T-helper (Th)-17 pathway have been approved for several inflammatory diseases. Interleukin (IL)-17 is involved in anti-Candida host defense, and clinical trials suggested increased candidiasis ...
Linda Davidson, Juul M.P.A. van den Reek, Mariolina Bruno, Florence van Hunsel, Ron M.C. Herings, Vasiliki Matzaraki, Collins K. Boahen, Vinod Kumar, Hans M.M. Groenewoud, Frank L. van de Veerdonk, Mihai G. Netea, Elke M.G.J. de Jong, Bart Jan Kullberg   +12 more
doaj   +1 more source

Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study [PDF]

, 2023
Pustular and erythrodermic psoriasis are rare and difficult-to-treat conditions. It has recently been shown that interleukin (IL)-17 inhibitors can be very effective among patients with these forms of psoriasis; however, the potential of IL-23 inhibitors
Luca Mastorino, Carrera, Carlo Giovanni, Gianluca Avallone, Paolo Dapavo, Ribero, Simone, Mastorino, Luca, Dapavo, Paolo, Maronese, Carlo Alberto, Marzano, Angelo Valerio, Carlo Alberto Maronese, Giulia Murgia, Gabriele Roccuzzo, Pietro Quaglino, Simone Ribero, Carlo Giovanni Carrera, Angelo Valerio Marzano, Avallone, Gianluca, Silvia Alberti-Violetti, Murgia, Giulia, Quaglino, Pietro, Roccuzzo, Gabriele, Alberti-Violetti, Silvia   +21 more
core   +1 more source

Interleukin-23 inhibitors

, 2022
For adult patients with moderate to severe plaque psoriasis scheduled for systemic therapy, FDA-approved agents that act via interleukin-23 (IL-23) inhibition are guselkumab, tildrakizumab, and risankizumab.
Adisen, Esra
core   +1 more source